Calzada V - Search Results

1

Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies.

Sicco E, Baez J, Ibarra M, Fernández M, Cabral P, Moreno M, Cerecetto H, Calzada V. Sicco E, et al. Among authors: calzada v. Cancer Biother Radiopharm. 2020 May;35(4):262-270. doi: 10.1089/cbr.2019.3402. Cancer Biother Radiopharm. 2020. PMID: 32407201

2

Synthesis of 99mTc-nimotuzumab with tricarbonyl ion: in vitro and in vivo studies.

Garcia MF, Camacho X, Calzada V, Fernandez M, Porcal W, Alonso O, Gambini JP, Cabral P. Garcia MF, et al. Among authors: calzada v. Curr Radiopharm. 2012 Jan;5(1):59-64. doi: 10.2174/1874471011205010059. Curr Radiopharm. 2012. PMID: 22074480

3

A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.

Calzada V, Zhang X, Fernandez M, Diaz-Miqueli A, Iznaga-Escobar N, Deutscher SL, Balter H, Quinn TP, Cabral P. Calzada V, et al. Curr Radiopharm. 2012 Oct;5(4):318-24. doi: 10.2174/1874471011205040318. Curr Radiopharm. 2012. PMID: 22280117

4

Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab.

Camacho X, García MF, Calzada V, Fernández M, Porcal W, Alonso O, Gambini JP, Cabral P. Camacho X, et al. Among authors: calzada v. Curr Radiopharm. 2013 Mar;6(1):12-9. doi: 10.2174/1874471011306010003. Curr Radiopharm. 2013. PMID: 23035645

5

[(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model.

Camacho X, García MF, Calzada V, Fernández M, Chabalgoity JA, Moreno M, Barbosa de Aguiar R, Alonso O, Gambini JP, Chammas R, Cabral P. Camacho X, et al. Among authors: calzada v. Oncology. 2013;84(4):200-9. doi: 10.1159/000338961. Epub 2013 Jan 15. Oncology. 2013. PMID: 23328435

6

Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.

Calzada V, Garcia F, Fernández M, Porcal W, Quinn T, Alonso O, Gambini JP, Cabral P. Calzada V, et al. World J Nucl Med. 2013 Jan;12(1):27-32. doi: 10.4103/1450-1147.113953. World J Nucl Med. 2013. PMID: 23961253 Free PMC article.

7

Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody.

García MF, Calzada V, Camacho X, Goicochea E, Gambini JP, Quinn TP, Porcal W, Cabral P. García MF, et al. Among authors: calzada v. Curr Radiopharm. 2014;7(2):84-90. doi: 10.2174/1874471007666141128160449. Curr Radiopharm. 2014. PMID: 25429778 Review.

8

Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents.

Calzada V, García MF, Alonso-Martínez LM, Camachoc X, Goicochea E, Fernández M, Castillo AX, Díaz-Miqueli A, Iznaga-Escobar N, Montaña RL, Alonso O, Gambini JP, Cabral P. Calzada V, et al. Anticancer Agents Med Chem. 2016;16(9):1184-9. doi: 10.2174/1871520616666160310143828. Anticancer Agents Med Chem. 2016. PMID: 26961312

9

177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.

Camacho X, Calzada V, Fernandez M, Alonso O, Chammas R, Riva E, Gambini JP, Cabral P. Camacho X, et al. Among authors: calzada v. Curr Radiopharm. 2017;10(1):21-28. doi: 10.2174/1874471009666161010155246. Curr Radiopharm. 2017. PMID: 27748184

10

Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.

Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, Cabral P, Cerecetto H. Calzada V, et al. Bioorg Med Chem. 2017 Feb 1;25(3):1163-1171. doi: 10.1016/j.bmc.2016.12.026. Epub 2016 Dec 24. Bioorg Med Chem. 2017. PMID: 28089349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters